首页> 美国卫生研究院文献>BMC Cancer >Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

【2h】

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

机译：用曲妥珠单抗和芳香酶抑制剂作为HER2阳性和激素受体阳性转移性或局部晚期乳腺癌的一线治疗：随机对照试验的研究方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Summary of previous studies of first line ET+ anti-HER2 treatment for MBC

机译：先前研究MBC的第一线ET +抗HER2治疗研究摘要

著录项

期刊名称 BMC Cancer
作者
Changjun Wang; Yan Lin; Yidong Zhou; Feng Mao; Hanjiang Zhu; Jinghong Guan; Xiaohui Zhang; Songjie Shen; Xin Huang; Chang Chen; Ru Yao; Jialin Zhao; Qiang Sun;
展开▼
作者单位

展开▼
年(卷),期 2020(-1),-1
年度 2020
页码 -1
总页数 6
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：转移性乳腺癌;烧烤蛋白;芳香酶抑制剂;曲妥珠单抗;

相似文献

外文文献
中文文献
专利

1. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial [J] . Changjun Wang, Yan Lin, Yidong Zhou, BMC Cancer . 2020,第1期

机译：用曲妥珠单抗和芳香酶抑制剂作为HER2阳性和激素受体阳性转移性或局部晚期乳腺癌的一线治疗：随机对照试验的研究方案
2. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial [J] . Rimawi Mothaffar, Ferrero Jean-Marc, de la Haba-Rodriguez Juan, Journal of Clinical Oncology . 2018,第28期

机译：第一线曲妥珠单抗加上芳香酶抑制剂，有或没有Pertuzumab，在人表皮生长因子受体2阳性和激素受体阳性转移或局部晚期乳腺癌（pertain）：一个随机的开放标签期II试验
3. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [J] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, Trials . 2020,第1期

机译：Trastuzumab，Pertuzumab和Eribulin甲磺酸丁酯与曲妥珠单抗，Pertuzumab和紫罗兰作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势，III期的研究方案日本试验（JBCRG-M06 / Emerald）
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Trastuzumab pertuzumab and eribulin mesylate versus trastuzumab pertuzumab and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：曲妥珠单抗帕妥珠单抗和甲磺酸艾瑞布林与曲妥珠单抗帕妥珠单抗和紫杉烷作为一线或二线治疗HER2阳性局部晚期或转移性乳腺癌的一线或二线治疗：III期随机对照非劣效性的研究方案在日本试用（JBCRG-M06 / EMERALD）
7. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：校正至：Trastuzumab，Pertuzumab和Eribulin甲蛋白与曲妥珠单抗，Pertuzumab和紫杉烷作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势的研究方案，日本第三阶段试验（JBCRG-M06 / Emerald）

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅